SERPINA1 and alpha 1-antitrypsin deficiency: Phase II trials of AROAAT2001 (SEQUOIA) is underway to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, ARO-AAT, administered subcutaneously to participants with AATD (NCT03945292) [110].